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 Modulation of the amount of API in the preparation 
 Formulation of associations of API which, if present in the same 
preparation, may show greater efficacy 
 Therapeutic treatments for patients with different ages with 
special needs and/or different problems (children and elderly) 
 Treatments of patients with cancers or degenerative pathologies 
that cause a severe pain with characteristics that greatly vary from 
patient to patient 
THE GALENICS:  
AN ANSWER TO THE  HOSPITAL PECULIAR NEEDS 
NATIONAL 
CONTEXT 
DEVELOPING 
COUNTRIES 
 Customize the dosages and pharmaceutical forms according to the 
local needs of patients 
 Employ local staff, teaching them a new “job”, so that it will be 
possible to open suitable school 
 Minimize the financial commitment necessary to prepare these 
medicines, respecting the quality of medicinal products 
DIFFERENT COUNTRIES, SAME NEED OF QUALITY 
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AN ANSWER TO THE  HOSPITAL PECULIAR NEEDS 
ITALY 
PROJECT “POLO 
ONCOLOGICO DI  
TORINO” 
1. Extension of the stability of anticancer drugs 
2. Development of a method for monitoring the microbiological stability of 
the cytotoxic preparations 
CLINICAL STUDY 
PROTPROS 
Evaluation of chemopreventive activity of galenics, comparable to dietary 
supplement, containing lycopene, selenium and green tea polyphenols 
CLINICAL STUDY 
MONAPOL 
Evaluation of cholesterol-lowering activity of a galenic, comparable to a dietary 
supplement, containing monacolin k and policosanol in subjects with mild to 
moderate hypercholesterolemia uncomplicated unfamiliar: randomized 
controlled double-blind study 
 
DEVELOPING COUNTRIES (DC) 
A.P.P.A.® GALENIC LAB  
IN HAITI 
1. Study of oral liquid pediatric formulations 
2. Stability study of the prepared liquid pharmaceutical forms 
3. Development of a method for the preparation of sterile solutions 
(antibiotics and cytostatic drugs) 
4. Project for the introduction of new oral and sterile formulations for 
pediatric use 
The World Health Report 2006 - working together for health 
Chapter 1: Health workers: a global profile 
ACCESS TO HEALTH SERVICES:  
INEQUALITIES BETWEEN NORTH AND SOUTH OF THE WORLD 
«…water-borne diseases are not caused by lack of antibiotics but by 
dirty water, and by the political, social, and economic forces that fail to 
make clean water available to all; heart disease is caused not by a lack 
of coronary care units but by the lives people lead, which are shaped 
by the environments in which they live; obesity is not caused by moral 
failure on the part of individuals but by the excess availability of high-fat 
and high-sugar foods …» 
Borana Singing wells, Kenya 
PROBLEMS RELATED TO THE LIFE STILE 
“Closing the gap in a generation: Health equity through action on the 
social determinants of health” – WHO Commission on Social 
Determinants of Health - 2008 
Essential medicines are those that satisfy the priority health care needs of the 
population. They are selected with due regard to public health relevance, evidence on 
efficacy and safety, and comparative cost-effectiveness. 
Essential medicines are intended to be available within the context of functioning health 
systems at all times in adequate amounts, in the appropriate dosage forms, with 
assured quality and adequate information, and at a price the individual and the 
community can afford. 
ESSENTIAL MEDICINES  
 More than fifty percent of the population in the Region have no regular access to 
essential medicines.  
 Medicine supply and regulatory systems are weak 
 Financial as well as human resources are inadequate to ensure delivery of pharmaceutical 
services and ensure access to essential medicines.  
 Circulation of poor quality medicines, high medicine prices, unethical promotion and 
irrational use of medicines poses additional challenges. 
BUT… 
“IMPERFECT” COUNTERFEITS 
«these products contain the right components, with an 
incorrect concentration and/or formulation resulting in 
defective quality specifications. In the vast majority of cases, 
they are devoid of any therapeutic efficacy» 
COUNTERFEIT MEDICINES 
“CRIMINAL” COUNTERFEITS 
«they are apparently similar to the original medicinal product, 
but do not contain any active ingredient and can even include 
harmful or toxic substances. They are usually sold at high 
prices and for the treatment of serious pathologies. 
Consequences for users of criminal counterfeits can be fatal» 
Di Giorgio D. Counterfeit drugs. The phenomenon and 
enforcement activities. Milano: Tecniche nuove; 2010. 
А counterfeit medicine is one which is deliberately and fraudulently mislabeled with 
respect to identity and/or source. Counterfeiting can apply to both branded and generic 
products and counterfeit products may include products with the correct ingredients or with the 
wrong ingredients, without active ingredients, with insufficient active ingredients or with fake 
packaging. WHO - General information on counterfeit medicines 
F.Baratta, A. Germano, P. Brusa 
 
Diffusion of counterfeit drugs in 
developing Countries and stability 
of galenics stored for months 
under different conditions of 
temperature and relative humidity 
 
Croat Med J. 2012; 53: 173-184 
Analysis of 
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of medicinal 
products 
COUNTERFIET MEDICINES IN DC: ANALYSIS OF THE PHENOMENON 
F.Baratta, A. 
Germano, P. Brusa 
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PHARMACEUTICAL FORMS TESTS (Ph Eur) 
 Uniformity of content (2.9.6) 
 Uniformity of mass (2.9.5) 
 Disintegration (2.9.1) 
 Friability (2.9.7) 
 Hardness (2.9.8) 
 Sterility (2.6.1) 
16% 
32% 
65% 
3% 
www.progettoappa.it                 appa.onlus@unito.it 
A.P.P.A.® PROJECT 
PLANNING, CARRYING OUT, STARTING LABS IN ORDER TO PREPARE GALENIC 
MEDICINAL PRODUCTS AND RELATIVE QUALITY CONTROL IN DEVELOPING 
COUNTRIES  
 
FEDERAZIONE ORDINI 
FARMACISTI ITALIANI 
ORDINE DEI FARMACISTI 
PROVINCIA DI TORINO  
With the patronage of: 
and 
 HIGH PERCENTAGE OF COUNTERFEIT MEDICINES IN THE AREA 
 LOCAL POOR AVAILABILITY OF QUALITY MEDICINES   
 HIGH COST OF INDUSTRIAL MEDICINES 
 APPROVAL OF LOCAL AUTHORITIES 
 
BASIC CONDITIONS FOR OPENING 
A LAB FOR THE PREPARATION OF GALENIC MEDICINAL PRODUCTS 
Garouà - Cameroun N’Djamena - Tchad 
SAINT DAMIEN PAEDIATRIC HOSPITAL 
PORT-AU-PRINCE - HAITI 
A. STUDY OF ORAL LIQUID PEDIATRIC FORMULATIONS 
B. STABILITY TESTS OF THE ACTIVE MOLECULES AND OF THE 
PREPARATION IN ACCORDANCE WITH THE EMA GUIDELINES 
 
C. DEVELOPMENT OF A METHOD FOR THE PREPARATION OF 
STERILE SOLUTIONS (ANTIBIOTICS AND CYTOSTATIC DRUGS) 
HAITI: WHY? 
MEDICINAL PRODUCTS 
LOT API PROVENANCE RESULTS 
6C090 Acetazolamide 250 mg Haiti 
Unsatisfied:  
Uniformity of content  (2.9.6), Friability (2.9.7) 
0302609 Ampicillin 1g India 
Unsatisfied: 
Bacterial endotixins (2.6.14.) 
071202 Chloramphenicol  1g USA Suitable 
09K4840 A Phenobarbital 30 mg Haiti 
Unsatisfied: 
Friability (2.9.7), Hardness (2.9.8) 
08E2978-A 
Phenobarbital syrup 
18mg/5ml 
Haiti Suitable 
08111487 Propanolol 40mg Brasil 
Unsatisfied:  
Uniformity of content (2.9.6) 
L08111487 Spironolactone 25mg 
Domenican 
Republic 
Suitable 
PROBLEMS: 
 Method of preparation 
 Quality of industrial tablets 
 Stability of the preparations 
 Administration of capsules for the neonatal 
and paediatric treatment 
 
PREPARATION OF CAPSULES FOR CHILDREN 
FROM INDUSTRIAL HIGH-DOSE TABLETS 
PAEDIATRICS: WHY? 
CAPSULES PRODUCED IN 2010 
LOT API PROVENANCE RESULTS 
200910-A Acetazolamide 25 mg St Damien Hospital 
Unsatisfied:  
Uniformity of content (2.9.6) 
A-200S10-A Acetazolamide 25 mg St Damien Hospital Suitable 
121110-B Exp Captopril 1,25 mg St Damien Hospital 
Unsatisfied:  
Uniformity of mass (2.9.5) 
230610-C Phenytoin 10 mg St Damien Hospital Suitable 
230610-G Phenytoin 10 mg St Damien Hospital Suitable 
 A. STUDY AND FORMULATION OF ORAL LIQUID PAEDIATRIC 
FORMULATIONS:  
 
METHODOLOGICAL  APPROACH 
In agreement whit local medical doctors the drugs for the paediatric 
therapy are chosen and then formulated: liquid oral formulations are 
preferred and appropriate excipients are selected. 
 
For each formulation a specific card (written in local language) has 
been prepared. The card shows the procedure of preparation and the 
characteristics of each component present in the formulation. 
 
Each preparation have been tested to check its quality and its stability 
under different environmental conditions in accordance with the EMA 
guidelines.  
A.P.P.A.® GALENIC LAB IN HAITI 
PREPARATIONS PEDIATRIQUES 
SIROPS 
ACIDE ASCORBIQUE 10 mg/ml 
CANREONATE  DE POTASSIUM 1 mg/ml 
FER SULFATE 5 mg/ml 
IBUPROFENE 20 mg/ml 
PROPANOLOL 0,5 mg/ml 
RANITIDINE 15 mg/ml 
SALBUTAMOL 0,4 mg/ml 
VITAMINE B6 1 mg/ ml 
SOLUTIONS 
CAPTOPRIL 1 mg/ml 
FUROSEMIDE 1 mg/ml 
GOUTTES 
NIFEDIPINE 1 mg/gtt 
RANITIDINE  4 mg/gtt 
SALBUTAMOL 0,2 mg/gtt 
VITAMINE B6 0,5 mg/gtt 
SUSPENSIONS 
VITAMINE B COMPLEX 5,8 mg/ml 
MAGNESIUM ET ALUMINIUM HYDROXYDE 200 
mg/ml 
Saint Damien Hospital 
0 
B. STABILITY STUDY OF THE PREPARED  
LIQUID PHARMACEUTICAL FORMS 
STORAGE  
CONDITION 
T (°C) RH PERIOD COVERED BY DATA ANALYTICAL METHOD 
Standard 25±2 60±5% 
12 months, analysis at time zero (T0) 
and every 30 days  
(from TS-1 to TS-12) 
UV-VIS 
spectrophotometric assay 
Refrigerator 5±3 - 
12 months, analysis at time zero (T0) 
and every 30 days  
(from TR-1 to TR-12) 
Accelerated 40±2 60±5% 
3 months, analysis at time zero (T0) 
and every 30 days  
(from TA-1 through TA-3) 
EMA Guideline on stability testing: stability testing of existing active substances and related finished products, 
2003, CPMP/QWP/122/02, rev 1 corr 
A.P.P.A.® GALENIC LAB IN HAITI 
Method: 
EVALUATION OF THE EXPIRATION DATE 
VALIDITY PERIOD:  
3 MONTHS 
housing and environmental conditions 
are not suitable for a proper storage of 
the preparations 
BUT 
The stability has been 
demonstrated  
for 12 MONTHS for  
all formulations 
PREPARATIONS PEDIATRIQUES 
SIROPS 
ACIDE ASCORBIQUE 10 mg/ml 
CANREONATE  DE POTASSIUM 1 mg/ml 
FER SULFATE 5 mg/ml 
IBUPROFENE 20 mg/ml 
PROPANOLOL 0,5 mg/ml 
RANITIDINE 15 mg/ml 
SALBUTAMOL 0,4 mg/ml 
VITAMINE B6 1 mg/ ml 
SOLUTIONS 
CAPTOPRIL 1 mg/ml 
FUROSEMIDE 1 mg/ml 
GOUTTES 
NIFEDIPINE 1 mg/gtt 
RANITIDINE  4 mg/gtt 
SALBUTAMOL 0,2 mg/gtt 
VITAMINE B6 0,5 mg/gtt 
SUSPENSIONS 
VITAMINE B COMPLEX 5,8 mg/ml 
MAGNESIUM ET ALUMINIUM HYDROXYDE 200 mg/ml 
STABILITY STUDY: RESULTS 
Galenics, in accord with the European Law (Ph Eur), must guarantee “the quality 
as a fundamental support to the security and the efficacy” 
PHARMACEUTICAL FORMS TESTS (Ph Eur) 
Uniformity of content (2.9.6) 
Uniformity of mass (2.9.5) 
Disintegration (2.9.1) 
Friability (2.9.7) 
Hardness (2.9.8) 
Sterility (2.6.1) 
STABILITY TESTS 
(EMA) 
D.C. 
ITALY 
PHARMACEUTICAL FORMS TESTS 
 
Ointments for skin application; Suppositories: 
•Verify of accuracy of followed procedures 
•Control of aspect 
•Control of the amount to sell 
•Control of the solidity of packing 
 
Stiff capsules: 
•Verify the accuracy of followed procedures 
•Control of aspect and solidity of capsules 
•Control of the number of capsules prepared 
•Mass uniformity of capsules 
 
Liquid medicinal products: 
•Verify the accuracy of followed procedures 
•Control of the amount of product to sell 
•Control of the solidity of packing 
RAW MATERIALS: Organoleptic control  
Melting point  
QUALITY CONTROL AND QUALITY ASSURANCE 
QUALITY CONTROL AND QUALITY ASSURANCE 
ANALYSIS METHOD REF. ACCEPTANCE CRITERIA 
General aspect Visual Posological unit integrity 
Uniformity of 
content 
Ph. Eur. 7 ed. 
Assay 2.9.6 
Each individual content is between 85% and 115% of the average 
content (10 dosage units) 
Uniformity of 
mass 
Ph. Eur. 7 ed. 
Assay 2.9.5 
Not more than two of the individual masses deviate from the average 
mass by more than ± 10% and none deviates by more than ±20% (20 
dosage units) 
Disintegration 
Ph. Eur. 7 ed. 
Assay 2.9.1 
At the end of the specified time all of the dosage units must have 
disintegrated completely 
Friability 
Ph. Eur. 7 ed. 
Assay 2.9.7 
Maximum loss of mass not more than 1% 
Hardness 
Ph. Eur. 7 ed. 
Assay 2.9.8 
Hardness between 3 and 12 N 
Sterility test  
Ph. Eur. 7 ed. 
Assay 2.6.1 
At intervals during the incubation period and at its conclusion, examine 
the media for macroscopic evidence of microbial growth: If no 
evidence of microbial growth is found, the product to be examined 
complies with the test for sterility 
Bacterial 
endotoxins  
Ph. Eur. 7 ed. 
Assay 2.6.14 
The test is considered valid when all replicates of tested solutions 
show no reaction and the result of control solution confirms the 
labelled lysate sensitivity. 
STANDARDIZATION OF RESULTS  
LOW COSTS 
SIMPLE EXECUTION 
SPECTOPHOTOMETRY UV/VIS 
“…reuse, repair equipment and goods instead of throwing them in a landfill, exceeding the 
consumerist obsession of the obsolescence of objects and the tension to the new…”  
A. Salza “Niente. Come si vive quando manca tutto. Antropologia della povertà estrema”, 
Sperling & Kupfer 2009 
Application of specific procedures for the preparation of: 
Lyophilized medicinal products 
Infusion bags 
Solutions 
C. DEVELOPMENT OF A METHOD FOR THE PREPARATION OF STERILE 
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CLINICAL STUDY MONAPOL 
Cooperation between Dept. of Scienza e Tecnologia del Farmaco of Turin,  
Order of Pharmacists of the Province of Turin 
Monascus 
purpureus 
fermentation on rice •monacolins (monacolin k): high affinity for the 
HMG-CoA reductase enzyme  
• action given by a set of factors not strictly related 
to monacolin k 
Policosanols 
• ↓LDL, ↓ triglycerides 
• ↑HDL 
To verify the profiles of effectiveness and tolerability of a galenic 
comparable to a dietary supplement containing a dry extract of 
fermented red rice by Monascus purpureus associated with another one 
titrated in policosanols 
OBJECTIVE 
MONAPOL STUDY: FLOW CHART 
210 subjects, presenting mild to moderate, uncomplicated, unfamiliar hypercholesterolemia, currently 
outside indication comparing to the start of treatment with inhibitors of HMG-CoA reductase 
 3 groups of treatment: pure vs control vs placebo; 
 2 phases  
 2 cps/day for three months; 
 Evaluation of plasmatic concentration: basal and after 3 months of treatment; 
 Blood analysis:  basal and after 3 months of treatment; 
 Self diagnostic evaluation: baseline, after 45 days (only in phase I) and after 3 months of treatment; 
 Chance of participate in a subsequent open-label treatment for a period of three months. 
Department of Scienza e Tecnologia del Farmaco (TO)  
A. EVALUATION OF THE CORRECT DOSAGE AND SET UP OF GALENIC 
FORMULATION  
B. STABILITY TESTS OF THE ACTIVE MOLECULES AND OF THE PREPARATION IN 
ACCORDANCE WITH THE EMA GUIDELINES 
C. EVALUATION OF PLASMATIC CONCENTRATION BY HPLC ANALYSIS 
A. EVALUATION OF THE CORRECT DOSAGE AND SET UP OF GALENIC FORMULATION  
Literature evaluation 
Evaluation of the legislation in force 
Application of specific procedures for the preparation of stiff cps 
Quality and assurance  control based on FU XII - Ph Eur assays 
 
GALENIC FORMULATION: STIFF CAPSULES 
Administration: 2 cps / day 
Group 1 (galenic preparation similar to a food supplement): 
Dose administered per day: monacolin k 3 mg/day, policosanol 20 mg/day 
Components: 
 Red yeast rice extract: title in monacolin k equal to 3.1%; 
 Biocosanol®: title in policosanol equal to 91.2% of which hexacosanol 14.7%, octacosanol 56.1%, 
triacontanol 20.4%; 
 Maize starch pregelatinised: q.b. 
  Group 2 (active pharmaceutical ingredient): 
Dose administered per day: lovastatin 3 mg/die 
Components: 
 Lovastatin: 1,5 mg/cps; 
 Maize starch pregelatinised: q.b. 
  Group 3 (placebo): 
Components: Maize starch pregelatinised : q.b. 
 
 
 
STORAGE  
CONDITION 
T (°C) RH PERIOD COVERED BY DATA ANALYTICAL METHOD 
Standard 25±2 60±5% 
12 months, analysis at time zero (T0) 
and every 30 days  
(from TS-1 to TS-12) 
UV-VIS 
spectrophotometric assay 
Refrigerator 5±3 - 
12 months, analysis at time zero (T0) 
and every 30 days  
(from TR-1 to TR-12) 
Accelerated 40±2 60±5% 
3 months, analysis at time zero (T0) 
and every 30 days  
(from TA-1 through TA-3) 
B. GALENIC FORMULATION:  STABILITY STUDY 
EMA Guideline on stability testing: stability testing of existing active substances and related finished products, 
2003, CPMP/QWP/122/02, rev 1 corr 
Method: 
Results: 
All formulations have proved to be 
stable in “Refrigerated” conditions (RT-
24) and “Standard” conditions (ST-24) 
for 24 months, in “Accelerated” 
conditions (AT-3)  for 3 months 0 
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Developing of an HPLC method (UV detector) to evaluate the monacolin k concentration 
in the plasma of enrolled subjects 
C. EVALUATION OF PLASMATIC CONCENTRATION BY HPLC ANALYSIS 
Mobile phase: 0.1% phosphoric acid - acetonitrile, flow rate: 0.5 ml / min, λ = 238 nm 
HiQ sil column C18HS, 3um, 4.6 mm L IDx100mm 
HPLC composed by: Biotech model 2003 degasser; CBM-10A Shimadzu  communications bus module; SPD-
10° VP Shimdzu UV-Vis detector; LC-10AD VP Shimadzu liquid cromatograph 
Stoch solution (SSm) of monacolin K Plasma enriched with SSm 
200 ng 
400 ng 
533 ng 
200 ng 
400 ng 
533 ng 
Stoch solution (SSl) of lovastatin 
200 ng 
400 ng 
533 ng 
200 ng 
400 ng 
533 ng 
Plasma enriched with SSl  
Overlapping of a 
baseline analysis (green) 
and quarterly (red) in 
the plasma of a subject 
probable peak of 
monacolin k 
The application of a standard procedure for the preparation the galenics administered 
during the study can guarantee their stability for 24 months. 
 
The developed HPLC procedure allows to highlight the concentration of monacolin k in the 
plasma of enrolled subjects 
 
 Actually 31 subjects have been enrolled.  
 The phase I of the study is finished and the phase II of the study is in progress. 
CONCLUSIONS 
MINISTERO DELLA SALUTE: LINEE GUIDA SUGLI INTEGRATORI ALIMENTARI 
 
SOSTANZE CON APPORTO MASSIMO GIORNALIERO DEFINITO 
Rextat® 
Lovinacor® 
Tavacor® 
LOVASTATINA 10 mg 
Indicazioni terapeutiche riportate in RCP 
Ipercolesterolemia primaria inclusa l’ipercolesterolemia familiare o 
l’iperlipemia mista (tipo IIa e IIb) quando la sola risposta alla dieta 
e ad altre misure non farmacologiche (aumento dell’attività fisica e 
se indicato riduzione del peso corporeo) sia risultata inadeguata. 
Ipercolesterolemia non corretta dalla sola dieta in soggetti ad alto 
rischio di un evento cardiovascolare maggiore (soggetti con rischio 
superiore del 20%, colesterolo totale maggiore di 190 mg/dl e 
colesterolo LDL maggiore di 115 mg/dl). Ipercolesterolemia non 
corretta dalla sola dieta in pazienti con cardiopatia ischemica, per la 
riduzione del rischio di infarto del miocardio. 
